Digimed Updates is the leading online destination for healthcare professionals, offering the medical news, expert perspectives and essential point of care
Don’t miss: ATTAIN-1 Phase 3 (orforglipron in obesity), EASD’s first guideline on diabetes distress, and precision medicine in T1D & T2D. More deep dives coming.
#EASD2025#Obesity#T1D#T2D#DigimedUpdates@diaindiatrust
EASD’s Statements & Guidelines committee highlights the GRADE framework for clinical guidelines, consensus docs & position statements—turning high-level evidence into best practice.
#Guidelines#EvidenceBased#EASD2025#DigimedUpdates@diaindiatrust
Another highlight: SOUL trial results on oral semaglutide are expected to clarify CV outcome benefits in T2D beyond glycemic control. Key data on whether benefits extend to heart, kidney and other systems.
#GLP1#EASD2025#DigimedUpdates@diaindiatrust
Major trial to watch: SURPASS-CVOT (Tirzepatide vs Dulaglutide in T2D). Early data: non-inferior for MACE, plus 16% lower all-cause mortality with Tirzepatide. Full results Sept 18.
#EASD2025#T2D#CVOT#DigimedUpdates@diaindiatrust
Unlock the latest in diabetes care! Join us for Learnings from ADA 2025 on 20th July, 8:30 PM IST with expert insights on inhaled insulin and diabetic neuropathy.
Webinar Link: https://t.co/Wl19XtRbtv
#ADA2025#DiabetesCare#IDFSEA#MedicalUpdate#DiabetesExperts
🌍 Join us for IDF Learnings 2025
📅 Date: 3rd May 2025 | 🕗 Time: 8:00 PM IST onwards
🎙 Featuring global diabetes experts from India, Bangladesh, Sri Lanka & UK
Register Now: https://t.co/cPFajPIQ0E
#DiabetesCare #IDFLearnings #MedicalEducation #Lupin #HCPEngagement #DiabetesAwareness #idfSoutheastasia